Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

Breast Cancer Clinical Trial

— SWITCH  

Official title:

Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01446185
• Other study ID #: 2010-A00577-32
• Secondary ID: 2010-A00577-32
• Status: Completed
• Phase: N/A
• First received: September 1, 2010
• Last updated: April 17, 2013
• Start date: January 2011
• Est. completion date: May 2012

Study information

• Verified date: April 2013
• Source: Genomic Health®, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Primary objective:

Determine the impact of the Oncotype DX Recurrence Score (RS) on the treatment recommendation made (administration of chemotherapy or not, in addition to hormonotherapy) in a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population.

The impact of Oncotype DX on treatment recommendations can be either a decrease in treatment intensity defined as a change in treatment recommendation from chemotherapy plus hormonal therapy to hormonal therapy alone or an increase in treatment intensity defined as a movement from hormonal therapy alone to the addition of chemotherapy to hormonal therapy.

Patients with HR+, N- breast cancer currently represent around 70% of newly diagnosed breast cancers. These are usually good prognosis tumors. However, on the basis of classical clinical and pathological prognostic parameters and markers, the international consensus guidelines recommend treatment with hormone- and chemotherapy in 85-95% of the cases. Considering the natural disease history, such as documented by the EBCTCG meta-analysis, more than 50% of these patients are overtreated, which leads to unnecessary side effects and costs to the health system and to the society.

Oncotype DX appears to be well adapted to therapeutic de-escalation as it targets HR+, N- patients and is performed on fixed paraffin embedded tissue (FPET). It is therefore best adapted to daily clinical practice as it does not necessitate any specific surgical procedure or tissue freezing.

The prognostic and predictive value of Oncotype DX in ER+, N- patients has been validated on three large adjuvant randomized trials (NASBP B-14, NSABP B-20, and the ATAC study). The test has been commercially available in the USA since 2004, and is being used for more than 50% of the HR+ N- patients in this country.

While Oncotype DX has been validated in the USA, it needs to be independently evaluated in France, in the context of the local treatment guidelines and habits, to provide data that are meaningful to the French health system and to the French medical community.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients > 18 years old.

2. Pre- or post- menopausal women with breast adenocarcinoma, confirmed by a pathologist and who underwent surgery, with a maximum of 4 weeks between surgery and the 2nd therapeutic decision with Oncotype DX.

3. HR positive (at least ER+) breast cancer patients (defined by a threshold of 10% of the cells IHC + without N- or pN1(mi), Her2 - (IHC0, 1, 2+ or FISH -)

4. Patients must be eligible to receive adjuvant chemotherapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity.

5. Patients must have given a written informed consent.

Exclusion Criteria:

1. T3 or T4, HR-, N+ (except pN1 (mi) (sn), Her2+ (IHC 3+ or Fish+) patients.

2. Metastatic patients.

3. Patients who cannot give an informed consent.

4. Patients who cannot receive chemotherapy.

5. Patient who participated in another clinical trial and is still in the exclusion period of any other trial.

6. Mentally disabled patient who has no legal responsibility for herself.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Device:
• Oncotype DX breast cancer test
The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.

Locations

Country	Name	City	State
France	CHRU Besançon	Besançon
France	Centre Jean Perrin	Clermont-Ferrand
France	Centre Val d'Aurelle	Montpellier
France	Centre Azuréen de Cancérologie	Mougins
France	Centre d'Oncologie Médicale de Gentilly	Nancy
France	Hôpital TENON	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Genomic Health®, Inc.	Registrat-Mapi

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	impact of the Oncotype DX Recurrence Score on the treatment recommendation made	The impact of Oncotype DX on treatment recommendations can be either a decrease in treatment intensity defined as a change in treatment recommendation from chemotherapy plus hormonal therapy to hormonal therapy alone or an increase in treatment intensity defined as a movement from hormonal therapy alone to the addition of chemotherapy to hormonal therapy.	Day 15	No
Secondary	Level of confidence of the physicians relating to their treatment recommendation before and after Oncotype DX RS results	The change in physicians' level of confidence in the treatment recommendation will be measured by the change from baseline to follow-up responses.	Day 15	No
Secondary	Physicians' perceptions regarding the utility of the Oncotype DX.		Day 15	No